Revance Therapeutics Inc (RVNC)

[DewDiligence]

Daxxify’s price premium to Botox in aesthetic procedures is already being reduced, according to your post in #msg-172590944.

The 10-40% price premium to Botox that RVNC first mentioned on the 4Q22 CC (#msg-171329878) is probably too steep at the upper end of this range. Hence, if what you say in #msg-172590944 is really happening, it’s a positive development for RVNC, IMO.